Royal Bank of Canada Issues Positive Forecast for Prestige Consumer Healthcare (NYSE:PBH) Stock Price

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) had its price target lifted by Royal Bank of Canada from $96.00 to $97.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a "sector perform" rating on the stock. Royal Bank of Canada's price target would suggest a potential upside of 14.06% from the stock's current price.

A number of other research analysts have also recently commented on the stock. Raymond James upgraded shares of Prestige Consumer Healthcare to a "moderate buy" rating in a research note on Thursday, December 19th. Oppenheimer raised their target price on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a research report on Thursday, February 13th. Canaccord Genuity Group boosted their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a research note on Friday, February 7th. Sidoti lowered Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price objective for the company. in a research note on Monday, December 9th. Finally, StockNews.com upgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Tuesday, March 18th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Prestige Consumer Healthcare has an average rating of "Moderate Buy" and a consensus target price of $93.33.

Remove Ads

Prestige Consumer Healthcare Stock Performance

Shares of PBH traded down $0.33 on Friday, reaching $85.04. 306,771 shares of the stock traded hands, compared to its average volume of 259,213. The stock's 50-day moving average price is $82.86 and its 200-day moving average price is $78.79. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20. The firm has a market cap of $4.21 billion, a price-to-earnings ratio of 19.92, a P/E/G ratio of 2.69 and a beta of 0.46. Prestige Consumer Healthcare has a 12 month low of $62.35 and a 12 month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Equities analysts forecast that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Mary Beth Fritz sold 1,678 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $90.00, for a total value of $151,020.00. Following the completion of the sale, the senior vice president now directly owns 17,157 shares in the company, valued at approximately $1,544,130. This trade represents a 8.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 1.60% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC raised its stake in shares of Prestige Consumer Healthcare by 3.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,624,501 shares of the company's stock worth $126,274,000 after acquiring an additional 49,331 shares during the last quarter. Geode Capital Management LLC raised its position in Prestige Consumer Healthcare by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 1,348,745 shares of the company's stock worth $105,342,000 after purchasing an additional 21,951 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC bought a new position in Prestige Consumer Healthcare in the 4th quarter worth approximately $84,932,000. Invesco Ltd. lifted its holdings in Prestige Consumer Healthcare by 2.4% during the 4th quarter. Invesco Ltd. now owns 1,060,263 shares of the company's stock worth $82,796,000 after buying an additional 24,392 shares in the last quarter. Finally, Congress Asset Management Co. boosted its position in Prestige Consumer Healthcare by 5.0% in the 4th quarter. Congress Asset Management Co. now owns 908,742 shares of the company's stock valued at $70,964,000 after buying an additional 43,619 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.